Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANK-003 with adjuvant chemotherapy in solid tumors
NCT06897228Phase 1Recruiting
- Sponsor
- Shenzhen Celconta Life Science Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Jan 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PANK-003 in lung cancer, esophageal cancer, gastric cancer (GC) and 1 more, sponsored by Shenzhen Celconta Life Science Co., Ltd. Primary endpoints: Dose limiting toxicity at 21 days, Incidence of Treatment Related adverse events at 1 year and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
PANK-003
03
Conditions
lung canceresophageal cancergastric cancer (GC)breast cancer
Beyond the preview
Go deeper on NCT06897228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897228.